👋 Hey, let’s get into it. About a year after RFK Jr. “retired” all members of the CDC’s vaccine advisory committee and replaced them with vaccine skeptics, the FDA is suddenly pulling vaccine experts back into the room for an all-day COVID strain meeting. Guess vaccines are important again.

The agency will convene outside advisers today to discuss updating seasonal COVID shots for the now-dominant XFG variant, with presentations from the CDC, WHO working groups, and vaccine makers including Moderna, Pfizer, and Sanofi. Yes, the same WHO the U.S. technically withdrew from earlier this year.

Between RFK Jr.’s vaccine skepticism, former FDA Commissioner Marty Makary’s history of criticizing COVID vaccine policy, and the presence of the WHO, this meeting is almost guaranteed to be awkward.

💉 Lilly Buys Three Vaccine Companies for Up to $3.8B
Eli Lilly apparently decided the best way to build a vaccine business is to buy several at once. The pharma giant announced acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company in deals worth up to $3.8 billion combined, expanding into shingles, bacterial pathogens, and flavivirus vaccines. The Curevo acquisition alone could reach $1.5 billion and positions Lilly to challenge GSK’s Shingrix franchise. Meanwhile, LimmaTech gives Lilly a phase 1 Staph aureus vaccine program as antibiotic resistance keeps climbing globally. At this point, Lilly’s acquisition strategy increasingly feels less like a shopping spree and more like a company speedrunning corporate development.

🎤 Akeso And Summit’s ASCO Plenary Slot Just Raised The Pressure
Akeso, Inc. and Summit Therapeutics are heading into ASCO with one of the hottest oncology data readouts of the year, but the attention comes with a giant target attached. Their Harmoni-6 trial evaluating ivonescimab in first-line non-small cell lung cancer earned a coveted plenary session slot, instantly raising expectations around overall survival results. Analysts say the presentation will face intense scrutiny precisely because plenary-stage data gets dissected more aggressively than standard conference talks. If the study shows a survival advantage over PD-1 plus chemotherapy regimens, it could mark the first phase 3 trial to clear one of oncology’s toughest bars. Which is exactly why every oncology analyst on Earth is now sharpening their knives.

🧗 Astellas Is Preparing For Life After Xtandi
Astellas Pharma knows the Xtandi patent cliff is coming, and the company just unveiled a strategy that basically reads: cut costs, buy assets, survive turbulence. The pharma giant expects current Xtandi sales to peak around $13 billion before fading toward what it calls a “pipeline-led inflection point” later this decade. To offset the decline, Astellas plans to pursue more business development deals targeting moderately derisked assets while simultaneously squeezing out another $1.3 billion in cumulative cost savings by 2030. The company believes its current pipeline plus future acquisitions can eventually generate roughly $6 billion in additional revenue. Translation: the shopping spree continues, but finance is now sitting in the passenger seat holding the budget spreadsheet.

💸 Apogee Lands A $1.3B Lifeline For Its Eczema Drug
Apogee Therapeutics secured up to $1.3 billion in royalty financing from Blackstone Life Sciences to push its eczema challenger zumilokibart into phase 3 development. Earlier mid-stage data suggested the anti-IL-13 antibody could potentially compete with blockbuster drugs like Dupixent and Ebglyss based on cross-trial comparisons. Investors hoping for a buyout seemed less thrilled, sending shares lower despite the giant financing package. The structure gives Apogee near-term cash while Blackstone collects future royalties if the drug succeeds commercially. Biotech investors basically looked at a billion-dollar financing deal and still asked, “Cool… but where’s the acquisition?”

💰 Lantheus May Be Eyeing A $7B Exit
Radiopharma company Lantheus Holdings is reportedly weighing a potential $7 billion takeover offer from Curium Pharma as consolidation accelerates across nuclear medicine.

🦠 Gilead Finally Lands A Hepatitis D Approval
After a prior FDA rejection tied to manufacturing concerns, Gilead Sciences secured accelerated approval for Hepcludex, America’s first hepatitis D treatment.

💵 Olympus Drops $270M on Prostate Cancer Tech
Olympus Corporation will acquire BioProtect for $270 million, adding biodegradable spacer balloons designed to protect healthy tissue during prostate radiation treatment.

👁️ Outlook Therapeutics Wins An FDA Appeal Fight
Outlook Therapeutics convinced the FDA that its wet AMD eye drug demonstrated effectiveness after previously getting rejected three separate times. Talk about not taking no for an answer.

🤩 Kura’s Cancer Data Sparks $2B Buzz
Nearly 80% of patients saw tumor shrinkage after treatment with Kura Oncology’s darlifarnib plus Bristol Myers Squibb’s Krazati, prompting Mizuho analysts to peg the regimen as a potential $2 billion market opportunity.

⏳ AstraZeneca’s Breast Cancer Pill Faces Another Delay
AstraZeneca saw the FDA extend review timelines for camizestrant after advisers previously voted against backing the breast cancer treatment.

💉 Another Triple-G Obesity Rival In Da House
Kailera Therapeutics reported up to 16% weight loss in an early-stage trial for its triple-acting obesity injection partnered with Hengrui Pharmaceuticals.

For years, pharma executives treated Chinese biotech licensing deals like discovering a secret clearance aisle full of discounted pipeline assets. Faster clinical timelines, cheaper development costs, strong early data, and increasingly sophisticated science made China one of the hottest dealmaking markets in biotech.

Now Washington is looking at those same deals and asking whether America accidentally outsourced part of its innovation engine at the future cost of national security.

Lawmakers are pushing to expand the COINS Act, a national security law designed to restrict outbound U.S. investments into sensitive sectors like AI and semiconductors. Several China hawks in Congress now want biotech added to the list. That could eventually force companies to notify regulators before licensing Chinese drug assets or potentially restrict certain deal structures altogether.

The timing matters because China licensing has exploded. Big pharma companies have increasingly relied on Chinese biotech for oncology, immunology, and metabolic disease pipelines, while venture firms embraced “NewCo” structures where U.S. startups license Chinese assets in exchange for equity stakes. The arrangement gave American investors access to cheaper innovation while Chinese companies gained exposure to U.S. capital markets and commercialization pathways.

Critics argue the trend weakens domestic biotech by pushing capital overseas and making it harder for American startups to compete. Supporters counter that blocking those partnerships could slow drug development, hurt patients, and weaken America’s own competitiveness by cutting companies off from one of the fastest-growing innovation hubs in the world.

The reality is that both sides kind of have a point.

China’s biotech rise did not happen by accident. The country spent years building infrastructure, funding research ecosystems, streamlining clinical trial execution, and retaining scientific talent. Meanwhile, many U.S. biotech leaders argue America has spent the past few years making its own ecosystem harder to operate inside through policy instability, FDA turbulence, funding uncertainty, and mounting pricing pressure.

That’s why this debate feels bigger than licensing deals. It’s really becoming a referendum on whether America wants to compete by building faster…or by building walls.

That’s how many respondents in a new AlixPartners survey rated healthcare and life sciences industry distress levels at 7 or higher on a scale of 10. Regulatory uncertainty, pricing pressure, tariffs, and shifting FDA dynamics are creating a level of anxiety that many executives believe is worsening quarter by quarter. Less than 40% of operators even said they feel significantly prepared for what’s coming next.

Here’s what biotech Redditors are talking about:

🤔 Biotech Reddit Debates Why Preclinical Data Keeps Falling Apart
Redditors in r/biotech spent the week arguing over one of drug development’s most painful recurring themes: why promising preclinical programs keep collapsing in humans. Some users blamed incentives pushing companies to rush assets into the clinic before they’re fully optimized, especially when investors demand quick milestones. Others pointed fingers at weak animal models, internal politics, and organizations becoming allergic to critical questions once leadership commits to a program. The funniest part might have been project managers immediately entering the comments to defend themselves like someone had activated a bat signal…or more likely a mouse signal in this case.

🍁 Scientists Just Want To Smoke In Peace
A principal scientist asking whether recreational weed use hurts professional credibility accidentally launched one of the most relatable biotech Reddit threads of the month. The overwhelming consensus was basically: nobody cares, just don’t show up high or make it your entire personality. Several commenters warned that oversharing at work creates unnecessary career risk, while others pointed out that plenty of high-performing scientists quietly use cannabis outside the office. Corporate America may still be awkward about it, but biotech Reddit largely treated the debate like someone asking whether adults are allowed to drink wine after work.

🏭 CordenPharma Expands Its GLP-1 Manufacturing Empire
CordenPharma acquired peptide CDMO AmbioPharm, adding new manufacturing sites in South Carolina and Shanghai amid booming GLP-1 demand.

☢️ Niowave Breaks Ground On A $75M Isotope Facility
Niowave started construction on a Michigan radiopharmaceutical plant designed to boost production of cancer isotope Actinium-225.

🤖 Signos Wants AI To Become Your GLP-1 Accountability Partner
Signos raised $20 million and expanded its Dexcom partnership for its AI-powered glucose monitoring and weight-loss platform.

🧠 Kordata Dynamics Wants Clinical Trials To Think In Real Time
Kordata Dynamics emerged from stealth with an AI platform focused on processing neural data during clinical trials. The company, spun out of BIOS Health, wants to help researchers monitor patient responses in real time rather than waiting months for traditional trial analysis cycles. Its initial focus includes neuromodulation therapies for diseases like Alzheimer’s, Parkinson’s, epilepsy, and cardiovascular disorders. The timing aligns closely with the FDA’s recent push toward continuous real-time clinical data review, making Kordata’s launch feel very strategically timed.

🧊 May 28, 2002 — NASA Discovers Massive Water Ice On Mars
On this day, NASA announced that the Mars Odyssey spacecraft had detected enormous quantities of buried water ice beneath the Martian surface. Using gamma ray and neutron measurements, scientists discovered enough frozen water near the poles to fill Lake Michigan twice over. At the time, it was the strongest large-scale evidence yet that Mars once held significant amounts of water rather than losing it entirely to space. Six years later, the Phoenix lander physically confirmed the findings by literally digging into the Martian ice.

Imagine being the first scientist trying to explain buried ice on Mars back in 2002. Half the room was probably excited, while the other half immediately started pitching colonization PowerPoints and asking about Martian waterfront property.

That’s all for today. See you Tuesday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead